查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1601120

新型藥物輸送系統市場：按給藥途徑、模式和最終用戶分類 - 2025-2030 年全球預測

Novel Drug Delivery Systems Market by Route of Administration, Mode, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年新型給藥系統市值為138.3億美元，預計2024年將達150億美元，複合年成長率為9.17%，2030年將達255.7億美元。

調查方法涵蓋先進技術，旨在以受控方式輸送藥物化合物並改善治療結果。 NDDS 至關重要，因為它可以提高藥物的生物有效性、標靶特異性、減少給藥頻率並最大限度地減少副作用。這些系統在腫瘤學、神經病學、慢性病和其他精確藥物傳輸至關重要的領域中得到了高度利用。最終用途範圍主要包括醫院、診所和研究機構，它們是創新藥物傳輸技術的狂熱消費者。

主要市場統計
基準年[2023] 138.3億美元
預測年份 [2024] 150億美元
預測年份 [2030] 255.7億美元
複合年成長率（%） 9.17%

主要市場促進因素包括慢性病的增加、生物技術的技術進步以及製藥公司研發投資的增加。老年人口的增加和對有效疾病管理的需求也將推動市場成長。目前的商機在於奈米技術應用、個人化醫療、生物分解性的輸送系統以及非侵入性輸送方法（例如經皮吸收貼片和吸入器）的開發。為了利用這些機會，公司應專注於協作研究、策略夥伴關係以及智慧給藥系統的人工智慧和物聯網的整合。

然而，高開發成本、嚴格的法律規範以及複雜的生物相互作用所導致的潛在安全問題等挑戰仍然存在，這可能會阻礙市場成長。此外，製藥公司經常面臨智慧財產權問題，這些問題可能會阻礙創新和市場進入。專注於合規業務，同時精簡研發成本至關重要。此外，改善以患者為中心的輸送系統、擴展到新興市場以及解決需求未滿足的治療領域是創新的最佳途徑。市場的競爭性和動態性要求持續創新和策略敏捷性。透過優先考慮以客戶為中心的創新並利用尖端材料科學，公司可以實現最佳成長並保持市場相關性。

市場動態：揭示快速發展的新型給藥系統市場的關鍵市場洞察

新藥物輸送系統的市場正因供需的動態交互作用而轉變。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 慢性病盛行率和老年人口顯著增加
    • 控制釋放技術的進展
    • 政府核准新的藥物輸送系統
  • 市場限制因素
    • 與新型藥物輸送系統相關的現有局限性
  • 市場機會
    • 不斷進步開發新的藥物輸送系統
    • 越來越多採用自行注射裝置
  • 市場挑戰
    • 提供治療和藥物所需的併發症和專業知識

波特五力：開拓新型給藥系統市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢、解決弱點並避免潛在的挑戰，以確保更強大的市場地位。

PESTLE分析：了解外部對新給藥系統市場的影響

外部宏觀環境因素在塑造新型藥物傳輸系統市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解新型給藥系統市場的競爭狀況

對新型藥物輸送系統市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 新型給藥系統市場供應商定位矩陣績效評估

FPNV 定位矩陣是評估新型藥物傳輸系統市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。四個象限清楚且準確地分類供應商，幫助使用者辨識最能滿足其策略目標的合作夥伴和解決方案。

本報告提供了涵蓋關鍵重點領域的全面市場分析：

1. 市場滲透率：對當前市場環境的詳細回顧，包括行業主要企業的大量資料。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 慢性病盛行率和老年人口顯著增加
      • 控制釋放技術的進展
      • 政府核准新的給藥系統
    • 抑制因素
      • 與新藥物輸送系統相關的現有限制
    • 機會
      • 新型藥物輸送系統的開發不斷取得進展
      • 越來越多採用自行注射裝置
    • 任務
      • 施用治療劑和藥物所需的併發症和專業知識
  • 市場區隔分析
    • 給藥途徑：在慢性病管理中擴大採用注射給藥系統
    • 最終用戶：預算限制和容納更多病患的需求正在增加醫院中新型給藥系統的使用。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境
  • 客戶客製化

第6章 新藥物輸送系統市場：依給藥途徑

  • 注射給藥系統
  • 口服給藥系統
  • 肺部給藥系統
  • 經皮給藥系統

第7章按模式分類的新給藥系統市場

  • 受管制藥物傳輸系統
  • 調控藥物傳輸系統
  • 標靶給藥系統

第8章新藥物輸送系統市場：依最終用戶分類

  • 醫院
  • 研究中心
  • 專科診所

第9章北美及南美新給藥系統市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區新型給藥系統市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲新型給藥系統市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 全新的一站式藥物輸送商店
    • Viridian Therapeutics 宣布與藥物傳輸創新者 Enable Injections 合作
    • Kindeva Drug Delivery 收購高峰會 Biosciences

公司名單

  • Novartis AG
  • Societal CDMO
  • Johnson & Johnson Services, Inc.
  • AstraZeneca Plc
  • Abbott Laboratories
  • Sanofi SA
  • Terumo Medical Corporation
  • Pfizer Inc.
  • Thermo Fisher Scientific Inc.
  • Enable Injections, Inc.
  • Pacira BioSciences, Inc.
  • Bristol Myers Squibb Company
  • Lonza Group Ltd.
  • Spectrum Pharmaceuticals, Inc.
  • Cospheric LLC
  • Polysciences Inc.
  • Insulet Corporation
  • Bayer AG
  • West Pharmaceutical Services, Inc.
  • Mo-Sci Corporation
  • Merck KGaA
  • Boston Scientific Corporation
  • Merit Medical Systems, Inc.
  • GlaxoSmithKline PLC
  • F. Hoffmann-La Roche Ltd.
Product Code: MRR-02026C4CB9B9

The Novel Drug Delivery Systems Market was valued at USD 13.83 billion in 2023, expected to reach USD 15.00 billion in 2024, and is projected to grow at a CAGR of 9.17%, to USD 25.57 billion by 2030.

The scope of Novel Drug Delivery Systems (NDDS) encompasses advanced methodologies designed to deliver pharmaceutical compounds in a controlled manner to achieve improved therapeutic outcomes. NDDS are essential because they enhance drug bioavailability, target specificity, reduce dosing frequency, and minimize side effects. These systems are highly applicable in areas such as oncology, neurology, and chronic conditions where precise drug delivery is paramount. The end-use scope primarily includes hospitals, clinics, and research institutes, which are avid consumers of innovative drug delivery technologies.

KEY MARKET STATISTICS
Base Year [2023] USD 13.83 billion
Estimated Year [2024] USD 15.00 billion
Forecast Year [2030] USD 25.57 billion
CAGR (%) 9.17%

Key market drivers include the rising prevalence of chronic diseases, technological advancements in biotechnology, and increased R&D investments by pharmaceutical companies. The growing geriatric population and the need for efficient disease management also bolster market growth. Current opportunities lie in nanotechnology applications, personalized medicine, biodegradable delivery systems, and the development of non-invasive delivery methods like transdermal patches and inhalers. To capitalize on these opportunities, businesses should focus on collaborative research, strategic partnerships, and the integration of AI and IoT for smart drug delivery systems.

Nevertheless, challenges such as high development costs, stringent regulatory frameworks, and potential safety issues due to complex biological interactions persist, potentially impeding market growth. Moreover, pharmaceutical companies often face intellectual property rights issues, which can stall innovation and market entry. Rationalizing R&D expenditure while focusing on regulatory-compliant practices is crucial. Additionally, refining patient-centric delivery systems, expanding to emerging markets, and addressing therapeutic areas with unmet needs represent the best innovation avenues. The market's nature is highly competitive and dynamic, requiring continuous innovation and strategic agility. By prioritizing customer-centric innovation and leveraging cutting-edge materials science, companies can achieve optimal growth and maintain market relevance.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Novel Drug Delivery Systems Market

The Novel Drug Delivery Systems Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevalence of Chronic Diseases and Significant Rise in Geriatric Population
    • Advancements in Controlled Drug Release Technologies
    • Government Approvals for Novel Drug Delivery Systems
  • Market Restraints
    • Existing Limitations Associated with Novel Drug Delivery System
  • Market Opportunities
    • Ongoing Advancements for Development of Novel Drug Delivery Systems
    • Rising Adoption of Self-Injectable Devices
  • Market Challenges
    • Complications and Expertise Required in Delivering Therapeutics and Drugs

Porter's Five Forces: A Strategic Tool for Navigating the Novel Drug Delivery Systems Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Novel Drug Delivery Systems Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Novel Drug Delivery Systems Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Novel Drug Delivery Systems Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Novel Drug Delivery Systems Market

A detailed market share analysis in the Novel Drug Delivery Systems Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Novel Drug Delivery Systems Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Novel Drug Delivery Systems Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Novel Drug Delivery Systems Market, highlighting leading vendors and their innovative profiles. These include Novartis AG, Societal CDMO, Johnson & Johnson Services, Inc., AstraZeneca Plc, Abbott Laboratories, Sanofi S.A., Terumo Medical Corporation, Pfizer Inc., Thermo Fisher Scientific Inc., Enable Injections, Inc., Pacira BioSciences, Inc., Bristol Myers Squibb Company, Lonza Group Ltd., Spectrum Pharmaceuticals, Inc., Cospheric LLC, Polysciences Inc., Insulet Corporation, Bayer AG, West Pharmaceutical Services, Inc., Mo-Sci Corporation, Merck KGaA, Boston Scientific Corporation, Merit Medical Systems, Inc., GlaxoSmithKline PLC, and F. Hoffmann-La Roche Ltd..

Market Segmentation & Coverage

This research report categorizes the Novel Drug Delivery Systems Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Route of Administration, market is studied across Injectable Drug Delivery Systems, Oral Drug Delivery Systems, Pulmonary Drug Delivery Systems, and Transdermal Drug Delivery Systems.
  • Based on Mode, market is studied across Controlled Drug Delivery Systems, Modulated Drug Delivery Systems, and Targeted Drug Delivery Systems.
  • Based on End-User, market is studied across Hospital, Research Centers, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of Chronic Diseases and Significant Rise in Geriatric Population
      • 5.1.1.2. Advancements in Controlled Drug Release Technologies
      • 5.1.1.3. Government Approvals for Novel Drug Delivery Systems
    • 5.1.2. Restraints
      • 5.1.2.1. Existing Limitations Associated with Novel Drug Delivery System
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing Advancements for Development of Novel Drug Delivery Systems
      • 5.1.3.2. Rising Adoption of Self-Injectable Devices
    • 5.1.4. Challenges
      • 5.1.4.1. Complications and Expertise Required in Delivering Therapeutics and Drugs
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Route of Administration: Rising adoption of injectable drug delivery systems for chronic disease management
    • 5.2.2. End-User: Increasing use of novel drug delivery systems in the hospital due to budget constraints and the necessity to cater to a larger patient base
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization

6. Novel Drug Delivery Systems Market, by Route of Administration

  • 6.1. Introduction
  • 6.2. Injectable Drug Delivery Systems
  • 6.3. Oral Drug Delivery Systems
  • 6.4. Pulmonary Drug Delivery Systems
  • 6.5. Transdermal Drug Delivery Systems

7. Novel Drug Delivery Systems Market, by Mode

  • 7.1. Introduction
  • 7.2. Controlled Drug Delivery Systems
  • 7.3. Modulated Drug Delivery Systems
  • 7.4. Targeted Drug Delivery Systems

8. Novel Drug Delivery Systems Market, by End-User

  • 8.1. Introduction
  • 8.2. Hospital
  • 8.3. Research Centers
  • 8.4. Specialty Clinics

9. Americas Novel Drug Delivery Systems Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Novel Drug Delivery Systems Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Novel Drug Delivery Systems Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Novel drug delivery one-stop shop
    • 12.3.2. Viridian Therapeutics Announces Partnership with Drug Delivery Innovator Enable Injections
    • 12.3.3. Kindeva Drug Delivery acquires Summit Biosciences

Companies Mentioned

  • 1. Novartis AG
  • 2. Societal CDMO
  • 3. Johnson & Johnson Services, Inc.
  • 4. AstraZeneca Plc
  • 5. Abbott Laboratories
  • 6. Sanofi S.A.
  • 7. Terumo Medical Corporation
  • 8. Pfizer Inc.
  • 9. Thermo Fisher Scientific Inc.
  • 10. Enable Injections, Inc.
  • 11. Pacira BioSciences, Inc.
  • 12. Bristol Myers Squibb Company
  • 13. Lonza Group Ltd.
  • 14. Spectrum Pharmaceuticals, Inc.
  • 15. Cospheric LLC
  • 16. Polysciences Inc.
  • 17. Insulet Corporation
  • 18. Bayer AG
  • 19. West Pharmaceutical Services, Inc.
  • 20. Mo-Sci Corporation
  • 21. Merck KGaA
  • 22. Boston Scientific Corporation
  • 23. Merit Medical Systems, Inc.
  • 24. GlaxoSmithKline PLC
  • 25. F. Hoffmann-La Roche Ltd.

LIST OF FIGURES

  • FIGURE 1. NOVEL DRUG DELIVERY SYSTEMS MARKET RESEARCH PROCESS
  • FIGURE 2. NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. NOVEL DRUG DELIVERY SYSTEMS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. NOVEL DRUG DELIVERY SYSTEMS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. NOVEL DRUG DELIVERY SYSTEMS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. NOVEL DRUG DELIVERY SYSTEMS MARKET DYNAMICS
  • TABLE 7. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INJECTABLE DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ORAL DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PULMONARY DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TRANSDERMAL DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CONTROLLED DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODULATED DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TARGETED DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. NOVEL DRUG DELIVERY SYSTEMS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 148. NOVEL DRUG DELIVERY SYSTEMS MARKET, FPNV POSITIONING MATRIX, 2023